Cabozantinib, a VEGFR2/MET/AXL inhibitor, is currently being investigated by our group in combination with pembrolizumab in the treatment of recurrent or metastatic incurable HNSCC (NCT03468218). The gene discussed is AXL; the disease is head and neck squamous cell carcinoma.